ACRV Nasdaq· Acrivon Therapeutics Inc
FundamentalsNews digest Peer analysis
ACRV Nasdaq· Acrivon Therapeutics Inc
Earnings report Q3 2023

ACRIVON THERAPEUTICS, INC. Reports Loss in Latest Quarter

Segments of Revenue

ACRIVON THERAPEUTICS, INC. did not generate any revenue in the latest quarter. The company stated that it does not expect to generate any revenue in the foreseeable future from drug sales. However, they mentioned the potential for revenue generation through collaboration agreements, which could include upfront fees, license fees, milestone-based payments, and reimbursements for research and development efforts.


Despite the lack of revenue, ACRIVON THERAPEUTICS, INC. showcased strength in its research and development efforts. The company's research and development expenses increased from $7.9 million in the previous year to $10.3 million in the latest quarter. This indicates a commitment to advancing their pipeline and potential future revenue streams.


The main weakness for ACRIVON THERAPEUTICS, INC. lies in its lack of revenue generation. The company has not been able to generate any revenue from drug sales and does not anticipate doing so in the near future. This poses a challenge in terms of sustaining operations and funding ongoing research and development efforts.


ACRIVON THERAPEUTICS, INC. reported a net loss of $14.5 million in the latest quarter, compared to a net loss of $9.2 million in the same quarter of the previous year. The increase in net loss can be attributed to higher operating expenses, particularly in research and development. The company also highlighted its focus on collaboration agreements as a potential source of future revenue.


ACRIVON THERAPEUTICS, INC. faced challenges in generating revenue in the latest quarter, as it did not generate any revenue from drug sales. However, the company demonstrated strength in its research and development efforts, with increased expenses in this area. The net loss for the quarter increased compared to the previous year, primarily due to higher operating expenses. ACRIVON THERAPEUTICS, INC. aims to generate revenue through collaboration agreements in the future.

Source documents

Form 10-Q  filed on Nov 09, 2023
4 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS missed by -4.90%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.